US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Landcadia Holdings IV Inc

10.54

0.0000

Volume:- -

Turnover:- -

Market Cap:142.91M

PE:103.68

High:10.54

Open:10.54

Low:10.54

Close:10.54

52wk High:10.54

52wk Low:10.54

Shares:13.56M

Float Shares:1.06M

Volume Ratio:- -

T/O Rate:- -

Dividend:- -

Dividend Rate:- -

EPS(TTM):0.1017

EPS(LYR):0.3860

ROE:--

ROA:-0.31%

PB:-24.43

PE(LYR):27.31

Loading ...

Overview Company News Filings

Opus Genetics Highlights 2025 Progress and Upcoming 2026 Catalysts

ICAO Approves Palm Oil Waste as a Base for Bioavtur

Press Release: Opus Genetics Announces Financial Results for Third Quarter 2025 and Provides Corporate Update

China's First Carbon Label for Freeze-Dried Kale Powder Launched in Gansu

Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Opus Genetics Featured on Good Morning America Spotlighting Breakthrough Gene Therapy Restoring Sight in Patients with Inherited Blindness

Bureau Veritas Showcases Three Key Net-Zero Transformation Solutions at Energy Taiwan

Opus Genetics to Participate in Chardan's 9th Annual Genetic Medicines Conference

Opus Genetics to Present at Upcoming Medical and Industry Conferences in October 2025

Opus Genetics Reports Positive Pediatric Data from OPGx-LCA5 Phase 1/2 Trial in Leber Congenital Amaurosis Type 5 (LCA5)

Envision Energy Earns "Green Passport" EPD, Raising the Benchmark for Sustainable Wind Turbines

Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Opus Genetics Doses First Patient in Pivotal LYNX-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients With Visual Disturbances Under Mesopic, Low-Contrast Conditions

Press Release: Opus Genetics Appoints Rob Gagnon as Chief Financial Officer

Opus Genetics Inherited Retinal Disease Programs Featured at Medical and Industry Conferences in September

Opus Genetics Announces FDA Clearance of IND Application for Gene Therapy Candidate OPGx-BEST1

Opus Genetics Announces Financial Results for Second Quarter 2025 and Provides Corporate Update

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/LCA/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"LCA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LCA\",,,,,undefined,":{"symbol":"LCA","market":"US","secType":"STK","nameCN":"Landcadia Holdings IV Inc","latestPrice":10.54,"timestamp":1770411600000,"preClose":10.54,"halted":0,"volume":0,"delay":0,"changeRate":0,"floatShares":1058523,"shares":13558523,"eps":0.101663,"marketStatus":"Market Closed","change":0,"latestTime":"02-06 16:00:00 EST","open":10.54,"high":10.54,"low":10.54,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0.101663,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1770627600000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":10.54,"volumeRatio":0,"impliedVol":1.24,"impliedVolPercentile":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LCA\",,,,,undefined,":{"symbol":"LCA","floatShares":1058523,"roa":"-0.31%","roe":"--","lyrEps":0.385996,"shares":13558523,"dividePrice":0,"high":10.54,"amplitude":0,"preClose":10.54,"low":10.54,"week52Low":10.54,"pbRate":"-24.43","week52High":10.54,"institutionHeld":0,"latestPrice":10.54,"eps":0.101663,"divideRate":0,"volume":0,"delay":0,"ttmEps":0.101663,"open":10.54,"prevYearClose":10.54,"prevWeekClose":10.54,"prevMonthClose":10.54,"prevQuarterClose":10.54},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/LCA\",params:#limit:5,,,undefined,":[{"market":"US","date":"2024-02-28","symbol":"LCA","reason":null,"defaultRemindTime":1709130600000,"announcedDate":"2024-02-15","type":"delisting","dateTimestamp":1709096400000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"LCA\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"LCA\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/LCA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"LCA","date":"2024-02-28","current":103.67587,"percent":0.59733,"low":11.488324,"twenty":30.050032,"median":45.140258,"eighty":66.415048,"high":224.854989,"avg":50.102288,"sd":30.317802,"marketCap":142906832},"quantilePoints":[{"date":"2021-03-26","current":67.434726,"twenty":34.822532,"median":44.259826,"eighty":66.87984,"marketCap":620000000},{"date":"2021-04-01","current":67.638662,"twenty":34.862598,"median":45.767827,"eighty":67.342317,"marketCap":621875000},{"date":"2021-04-09","current":67.910576,"twenty":34.954175,"median":46.295628,"eighty":67.665854,"marketCap":624375000},{"date":"2021-04-16","current":68.114512,"twenty":35.12016,"median":46.790631,"eighty":67.835015,"marketCap":626250000},{"date":"2021-04-23","current":67.978555,"twenty":35.320487,"median":47.879029,"eighty":67.947013,"marketCap":625000000},{"date":"2021-04-30","current":67.978555,"twenty":35.45213,"median":49.123129,"eighty":67.978555,"marketCap":625000000},{"date":"2021-05-07","current":67.842598,"twenty":35.486472,"median":50.06563,"eighty":67.978555,"marketCap":623750000},{"date":"2021-05-14","current":68.046533,"twenty":35.572327,"median":50.51803,"eighty":67.978555,"marketCap":625625000},{"date":"2021-05-21","current":65.39537,"twenty":35.938639,"median":50.78193,"eighty":67.978555,"marketCap":601250000},{"date":"2021-05-28","current":67.570684,"twenty":36.230544,"median":51.083531,"eighty":67.978555,"marketCap":621250000},{"date":"2021-06-04","current":67.638662,"twenty":36.310674,"median":51.837531,"eighty":67.978555,"marketCap":621875000},{"date":"2021-06-11","current":66.143134,"twenty":36.394254,"median":52.459581,"eighty":67.978555,"marketCap":608125000},{"date":"2021-06-18","current":66.483027,"twenty":36.512995,"median":53.157032,"eighty":67.978555,"marketCap":611250000},{"date":"2021-06-25","current":67.026855,"twenty":36.610243,"median":53.477482,"eighty":67.978555,"marketCap":616250000},{"date":"2021-07-02","current":66.279091,"twenty":36.655127,"median":54.174932,"eighty":67.978555,"marketCap":609375000},{"date":"2021-07-09","current":65.939198,"twenty":36.670088,"median":54.665033,"eighty":67.978555,"marketCap":606250000},{"date":"2021-07-16","current":66.007177,"twenty":36.737414,"median":55.362483,"eighty":67.972981,"marketCap":606875000},{"date":"2021-07-23","current":66.279091,"twenty":36.767336,"median":56.851634,"eighty":67.94946,"marketCap":609375000},{"date":"2021-07-30","current":65.939198,"twenty":36.767336,"median":57.247484,"eighty":67.937768,"marketCap":606250000},{"date":"2021-08-06","current":65.938518,"twenty":36.774817,"median":58.284235,"eighty":67.910576,"marketCap":606243750},{"date":"2021-08-13","current":65.939198,"twenty":36.812221,"median":60.546236,"eighty":67.910576,"marketCap":606250000},{"date":"2021-08-20","current":65.599305,"twenty":36.842143,"median":61.828037,"eighty":67.89698,"marketCap":603125000},{"date":"2021-08-27","current":65.905209,"twenty":36.842143,"median":63.147538,"eighty":67.842598,"marketCap":605937500},{"date":"2021-09-03","current":66.483027,"twenty":36.842143,"median":65.327391,"eighty":67.831007,"marketCap":611250000},{"date":"2021-09-10","current":66.285889,"twenty":36.842143,"median":65.39537,"eighty":67.784641,"marketCap":609437500},{"date":"2021-09-17","current":66.415048,"twenty":36.842143,"median":65.599305,"eighty":67.774619,"marketCap":610625000},{"date":"2021-09-24","current":66.34707,"twenty":36.842143,"median":65.599305,"eighty":67.706641,"marketCap":610000000},{"date":"2021-10-01","current":66.279091,"twenty":36.842143,"median":65.673742,"eighty":67.706641,"marketCap":609375000},{"date":"2021-10-08","current":66.34707,"twenty":36.879546,"median":65.735263,"eighty":67.638662,"marketCap":610000000},{"date":"2021-10-15","current":66.618984,"twenty":36.879546,"median":65.921864,"eighty":67.638662,"marketCap":612500000},{"date":"2021-10-22","current":66.143134,"twenty":36.879546,"median":65.939198,"eighty":67.638662,"marketCap":608125000},{"date":"2021-10-29","current":66.279771,"twenty":36.879546,"median":65.939198,"eighty":67.638662,"marketCap":609381250},{"date":"2021-11-05","current":66.754941,"twenty":36.879546,"median":65.939198,"eighty":67.570684,"marketCap":613750000},{"date":"2021-11-12","current":66.618984,"twenty":36.879546,"median":65.939198,"eighty":67.570684,"marketCap":612500000},{"date":"2021-11-19","current":66.618984,"twenty":36.879546,"median":65.939198,"eighty":67.502705,"marketCap":612500000},{"date":"2021-11-26","current":66.686962,"twenty":36.879546,"median":65.939198,"eighty":67.448322,"marketCap":613125000},{"date":"2021-12-03","current":66.618984,"twenty":36.879546,"median":65.984744,"eighty":67.434726,"marketCap":612500000},{"date":"2021-12-10","current":66.483027,"twenty":36.909812,"median":66.007177,"eighty":67.427112,"marketCap":611250000},{"date":"2021-12-17","current":66.211112,"twenty":36.97688,"median":66.007177,"eighty":67.411154,"marketCap":608750000},{"date":"2021-12-23","current":66.34707,"twenty":36.991756,"median":66.075155,"eighty":67.342317,"marketCap":610000000},{"date":"2021-12-31","current":66.143134,"twenty":37.014198,"median":66.143134,"eighty":67.298769,"marketCap":608125000},{"date":"2022-01-07","current":66.618984,"twenty":37.096484,"median":66.143134,"eighty":67.257982,"marketCap":612500000},{"date":"2022-01-14","current":66.143134,"twenty":37.161512,"median":66.143134,"eighty":67.108429,"marketCap":608125000},{"date":"2022-01-21","current":65.803241,"twenty":37.191435,"median":66.143134,"eighty":67.026855,"marketCap":605000000},{"date":"2022-01-28","current":65.803241,"twenty":37.216175,"median":66.143134,"eighty":67.026855,"marketCap":605000000},{"date":"2022-02-04","current":66.007177,"twenty":37.290981,"median":66.075155,"eighty":67.026855,"marketCap":606875000},{"date":"2022-02-11","current":66.007177,"twenty":37.506495,"median":66.075155,"eighty":66.999664,"marketCap":606875000},{"date":"2022-02-18","current":65.939198,"twenty":37.764475,"median":66.075155,"eighty":66.931685,"marketCap":606250000},{"date":"2022-02-25","current":66.007177,"twenty":38.188023,"median":66.041166,"eighty":66.890898,"marketCap":606875000},{"date":"2022-03-04","current":66.007177,"twenty":39.281235,"median":66.007177,"eighty":66.888686,"marketCap":606875000},{"date":"2022-03-11","current":66.279091,"twenty":39.349919,"median":66.041166,"eighty":66.87984,"marketCap":609375000},{"date":"2022-03-18","current":66.280451,"twenty":39.521628,"median":66.075155,"eighty":66.868456,"marketCap":609387500},{"date":"2022-03-25","current":66.34707,"twenty":40.225634,"median":66.075155,"eighty":66.816121,"marketCap":610000000},{"date":"2022-04-01","current":66.551005,"twenty":40.334382,"median":66.09215,"eighty":66.782132,"marketCap":611875000},{"date":"2022-04-08","current":66.551005,"twenty":40.609116,"median":66.143134,"eighty":66.754941,"marketCap":611875000},{"date":"2022-04-14","current":66.618984,"twenty":41.067006,"median":66.143134,"eighty":66.754941,"marketCap":612500000},{"date":"2022-04-22","current":66.686962,"twenty":41.210097,"median":66.143134,"eighty":66.754941,"marketCap":613125000},{"date":"2022-04-29","current":66.483027,"twenty":41.353188,"median":66.143134,"eighty":66.754941,"marketCap":611250000},{"date":"2022-05-06","current":66.551005,"twenty":41.639369,"median":66.143134,"eighty":66.754941,"marketCap":611875000},{"date":"2022-05-13","current":30.050032,"twenty":41.639369,"median":66.143134,"eighty":66.754941,"marketCap":610625000},{"date":"2022-05-20","current":29.927002,"twenty":40.494644,"median":66.143134,"eighty":66.754941,"marketCap":608125000},{"date":"2022-05-27","current":29.957759,"twenty":39.349919,"median":66.143134,"eighty":66.754941,"marketCap":608750000},{"date":"2022-06-03","current":29.957759,"twenty":37.609798,"median":66.143134,"eighty":66.754941,"marketCap":608750000},{"date":"2022-06-10","current":30.173062,"twenty":37.168227,"median":66.143134,"eighty":66.73422,"marketCap":613125000},{"date":"2022-06-17","current":30.050032,"twenty":36.97688,"median":66.143134,"eighty":66.72257,"marketCap":610625000},{"date":"2022-06-24","current":30.111547,"twenty":36.879546,"median":66.075155,"eighty":66.700558,"marketCap":611875000},{"date":"2022-07-01","current":30.111547,"twenty":36.879546,"median":66.075155,"eighty":66.686962,"marketCap":611875000},{"date":"2022-07-08","current":30.050032,"twenty":36.857104,"median":66.075155,"eighty":66.686962,"marketCap":610625000},{"date":"2022-07-15","current":30.050032,"twenty":36.842143,"median":66.041166,"eighty":66.686962,"marketCap":610625000},{"date":"2022-07-22","current":30.111547,"twenty":36.782298,"median":66.007177,"eighty":66.686962,"marketCap":611875000},{"date":"2022-07-29","current":30.111547,"twenty":36.685049,"median":66.007177,"eighty":66.686962,"marketCap":611875000},{"date":"2022-08-05","current":30.203819,"twenty":36.394254,"median":66.007177,"eighty":66.686962,"marketCap":613750000},{"date":"2022-08-12","current":30.203819,"twenty":35.543708,"median":66.007177,"eighty":66.686962,"marketCap":613750000},{"date":"2022-08-19","current":44.594207,"twenty":35.835613,"median":66.007177,"eighty":66.686962,"marketCap":612500000},{"date":"2022-08-26","current":44.639711,"twenty":36.201925,"median":66.007177,"eighty":66.686962,"marketCap":613125000},{"date":"2022-09-02","current":44.594207,"twenty":36.310674,"median":65.988823,"eighty":66.686962,"marketCap":612500000},{"date":"2022-09-09","current":44.616959,"twenty":36.369635,"median":65.96503,"eighty":66.686962,"marketCap":612812500},{"date":"2022-09-16","current":44.639711,"twenty":36.490553,"median":65.939198,"eighty":66.686962,"marketCap":613125000},{"date":"2022-09-23","current":44.685215,"twenty":36.595281,"median":65.939198,"eighty":66.673366,"marketCap":613750000},{"date":"2022-09-30","current":44.685215,"twenty":36.655127,"median":65.939198,"eighty":66.618984,"marketCap":613750000},{"date":"2022-10-07","current":44.867232,"twenty":36.670088,"median":65.939198,"eighty":66.618984,"marketCap":616250000},{"date":"2022-10-14","current":44.969617,"twenty":36.737414,"median":65.939198,"eighty":66.618984,"marketCap":617656250},{"date":"2022-10-21","current":45.049249,"twenty":36.767336,"median":65.939198,"eighty":66.618984,"marketCap":618750000},{"date":"2022-10-28","current":45.140258,"twenty":36.767336,"median":65.939198,"eighty":66.618984,"marketCap":620000000},{"date":"2022-11-04","current":45.185762,"twenty":36.774817,"median":65.939198,"eighty":66.618984,"marketCap":620625000},{"date":"2022-11-11","current":45.140713,"twenty":36.812221,"median":65.939198,"eighty":66.618984,"marketCap":620006250},{"date":"2022-11-18","current":33.101263,"twenty":36.737414,"median":65.888215,"eighty":66.618984,"marketCap":625000000},{"date":"2022-11-25","current":33.167465,"twenty":36.58032,"median":65.837231,"eighty":66.618984,"marketCap":626250000},{"date":"2022-12-02","current":33.233668,"twenty":36.144689,"median":65.803241,"eighty":66.618984,"marketCap":627500000},{"date":"2022-12-09","current":33.266769,"twenty":35.400618,"median":65.742061,"eighty":66.618984,"marketCap":628125000},{"date":"2022-12-16","current":33.266769,"twenty":34.828256,"median":65.735263,"eighty":66.618984,"marketCap":628125000},{"date":"2022-12-23","current":33.03506,"twenty":33.626294,"median":65.633634,"eighty":66.618984,"marketCap":623750000},{"date":"2022-12-30","current":33.167465,"twenty":33.311522,"median":65.599305,"eighty":66.618984,"marketCap":626250000},{"date":"2023-01-06","current":33.051611,"twenty":33.266769,"median":65.599305,"eighty":66.618984,"marketCap":624062500},{"date":"2023-01-13","current":33.001959,"twenty":33.253529,"median":65.39537,"eighty":66.618984,"marketCap":623125000},{"date":"2023-01-20","current":33.167465,"twenty":33.193218,"median":65.327391,"eighty":66.618984,"marketCap":626250000},{"date":"2023-01-27","current":33.233668,"twenty":33.167465,"median":63.147538,"eighty":66.618984,"marketCap":627500000},{"date":"2023-02-03","current":33.134364,"twenty":33.167465,"median":61.828037,"eighty":66.618984,"marketCap":625625000},{"date":"2023-02-10","current":33.134364,"twenty":33.147604,"median":60.546236,"eighty":66.618984,"marketCap":625625000},{"date":"2023-02-17","current":33.399174,"twenty":33.167465,"median":58.284235,"eighty":66.618984,"marketCap":630625000},{"date":"2023-02-24","current":33.233668,"twenty":33.167465,"median":57.304034,"eighty":66.618984,"marketCap":627500000},{"date":"2023-03-03","current":33.332971,"twenty":33.167465,"median":56.983584,"eighty":66.605388,"marketCap":629375000},{"date":"2023-03-10","current":33.29987,"twenty":33.167465,"median":55.720633,"eighty":66.551005,"marketCap":628750000},{"date":"2023-03-17","current":33.366073,"twenty":33.167465,"median":54.778133,"eighty":66.551005,"marketCap":630000000},{"date":"2023-03-24","current":33.233999,"twenty":33.167465,"median":54.174932,"eighty":66.551005,"marketCap":627506250},{"date":"2023-03-31","current":33.399174,"twenty":33.167465,"median":53.477482,"eighty":66.551005,"marketCap":630625000},{"date":"2023-04-06","current":33.332971,"twenty":33.167465,"median":53.251282,"eighty":66.551005,"marketCap":629375000},{"date":"2023-04-14","current":33.399174,"twenty":33.184016,"median":52.591531,"eighty":66.551005,"marketCap":630625000},{"date":"2023-04-21","current":33.399174,"twenty":33.188319,"median":51.931781,"eighty":66.551005,"marketCap":630625000},{"date":"2023-04-28","current":26.2563,"twenty":33.167465,"median":51.083531,"eighty":66.551005,"marketCap":629375000},{"date":"2023-05-05","current":26.2563,"twenty":33.167465,"median":50.78193,"eighty":66.551005,"marketCap":629375000},{"date":"2023-05-12","current":26.334521,"twenty":33.134364,"median":50.51803,"eighty":66.551005,"marketCap":631250000},{"date":"2023-05-19","current":51.891527,"twenty":33.134364,"median":50.63113,"eighty":66.551005,"marketCap":630937500},{"date":"2023-05-26","current":11.488324,"twenty":33.134364,"median":50.89503,"eighty":66.489825,"marketCap":139683972},{"date":"2023-06-02","current":11.522516,"twenty":33.134364,"median":50.59343,"eighty":66.484387,"marketCap":140099699},{"date":"2023-06-09","current":11.522516,"twenty":33.101263,"median":50.25413,"eighty":66.483027,"marketCap":140099699},{"date":"2023-06-16","current":11.522516,"twenty":33.064851,"median":49.160829,"eighty":66.483027,"marketCap":140099699},{"date":"2023-06-23","current":11.533913,"twenty":33.051611,"median":48.972329,"eighty":66.483027,"marketCap":140238274},{"date":"2023-06-30","current":11.556707,"twenty":33.049625,"median":47.879029,"eighty":66.483027,"marketCap":140515425},{"date":"2023-07-07","current":11.556707,"twenty":33.03506,"median":46.790631,"eighty":66.483027,"marketCap":140515425},{"date":"2023-07-14","current":11.619619,"twenty":33.008579,"median":46.295628,"eighty":66.483027,"marketCap":141280361},{"date":"2023-07-21","current":11.619619,"twenty":32.935756,"median":45.880927,"eighty":66.483027,"marketCap":141280361},{"date":"2023-07-28","current":11.659281,"twenty":32.869554,"median":45.185762,"eighty":66.483027,"marketCap":141762603},{"date":"2023-08-04","current":11.659281,"twenty":32.720598,"median":45.185762,"eighty":66.483027,"marketCap":141762603},{"date":"2023-08-11","current":11.647998,"twenty":30.203819,"median":45.185762,"eighty":66.483027,"marketCap":141625413},{"date":"2023-08-18","current":18.12164,"twenty":30.173062,"median":45.140258,"eighty":66.483027,"marketCap":142316904},{"date":"2023-08-25","current":18.174576,"twenty":30.142304,"median":45.128882,"eighty":66.483027,"marketCap":142732631},{"date":"2023-09-01","current":18.262625,"twenty":30.117698,"median":45.094754,"eighty":66.483027,"marketCap":143424122},{"date":"2023-09-08","current":18.262802,"twenty":30.111547,"median":45.094754,"eighty":66.483027,"marketCap":143425507},{"date":"2023-09-14","current":18.280447,"twenty":30.111547,"median":45.049249,"eighty":66.483027,"marketCap":143564083},{"date":"2023-09-22","current":18.52748,"twenty":30.111547,"median":45.049249,"eighty":66.483027,"marketCap":145504138},{"date":"2023-09-29","current":18.368673,"twenty":30.111547,"median":45.049249,"eighty":66.483027,"marketCap":144256960},{"date":"2023-10-06","current":18.403963,"twenty":30.080789,"median":44.969617,"eighty":66.483027,"marketCap":144534110},{"date":"2023-10-13","current":18.392494,"twenty":30.080789,"median":44.889984,"eighty":66.483027,"marketCap":144444036},{"date":"2023-10-20","current":18.351028,"twenty":30.050032,"median":44.776224,"eighty":66.483027,"marketCap":144118384},{"date":"2023-10-27","current":18.351204,"twenty":30.050032,"median":44.776224,"eighty":66.483027,"marketCap":144119770},{"date":"2023-11-03","current":18.368673,"twenty":30.050032,"median":44.730719,"eighty":66.483027,"marketCap":144256960},{"date":"2023-11-10","current":18.368673,"twenty":30.050032,"median":44.707967,"eighty":66.483027,"marketCap":144256960},{"date":"2023-11-17","current":18.298269,"twenty":30.032869,"median":44.696591,"eighty":66.483027,"marketCap":143704044},{"date":"2023-11-24","current":54.096492,"twenty":30.050032,"median":44.707967,"eighty":66.483027,"marketCap":140873053},{"date":"2023-11-30","current":54.200624,"twenty":30.050032,"median":44.730719,"eighty":66.483027,"marketCap":141144224},{"date":"2023-12-22","current":54.096492,"twenty":30.050032,"median":44.730719,"eighty":66.483027,"marketCap":140873053},{"date":"2023-12-29","current":54.25269,"twenty":30.050032,"median":44.776224,"eighty":66.483027,"marketCap":141279809},{"date":"2024-01-05","current":54.25269,"twenty":30.050032,"median":44.776224,"eighty":66.483027,"marketCap":141279809},{"date":"2024-01-12","current":54.513019,"twenty":30.050032,"median":44.889984,"eighty":66.428644,"marketCap":141957735},{"date":"2024-01-19","current":54.513019,"twenty":30.050032,"median":44.963929,"eighty":66.415048,"marketCap":141957735},{"date":"2024-01-26","current":54.877481,"twenty":30.050032,"median":45.049249,"eighty":66.415048,"marketCap":142906832},{"date":"2024-02-02","current":54.877481,"twenty":30.050032,"median":45.049249,"eighty":66.415048,"marketCap":142906832},{"date":"2024-02-09","current":54.513019,"twenty":30.050032,"median":45.049249,"eighty":66.415048,"marketCap":141957735},{"date":"2024-02-16","current":54.773349,"twenty":30.050032,"median":45.094754,"eighty":66.415048,"marketCap":142635661},{"date":"2024-02-23","current":54.877481,"twenty":30.050032,"median":45.128882,"eighty":66.415048,"marketCap":142906832},{"date":"2024-02-28","current":54.877481,"twenty":30.050032,"median":45.140258,"eighty":66.415048,"marketCap":142906832}],"updateTime":1770440076637},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"LCA\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2601369896","title":"Opus Genetics Highlights 2025 Progress and Upcoming 2026 Catalysts","url":"https://stock-news.laohu8.com/highlight/detail?id=2601369896","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601369896?lang=en_us&edition=fundamental","pubTime":"2026-01-08 20:00","pubTimestamp":1767873600,"startTime":"0","endTime":"0","summary":"- Multi-asset pipeline with significant targeted data readouts and milestones -- Two lead ophthalmic gene therapy programs in clinical trials with new data anticipated in 2026 -- Supplemental New Drug","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/08/3215226/0/en/Opus-Genetics-Highlights-2025-Progress-and-Upcoming-2026-Catalysts.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2065732104.USD","PRGS","BK4097","ARB","LCA"],"gpt_icon":0},{"id":"2590525597","title":"ICAO Approves Palm Oil Waste as a Base for Bioavtur","url":"https://stock-news.laohu8.com/highlight/detail?id=2590525597","media":"Tempo","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590525597?lang=en_us&edition=fundamental","pubTime":"2025-12-11 18:52","pubTimestamp":1765450357,"startTime":"0","endTime":"0","summary":"TEMPO.CO, Jakarta -The International Civil Aviation Organization  has approved the use of palm oil waste or Palm Oil Mill Effluent  as a raw material for bioavtur. Indonesia's Ministry of Transportation stated that this is a significant achievement in the effort to develop environmentally friendly aviation fuel.The Director General of Air Transportation, Lukman F. Laisa, stated that the result was announced after Indonesia submitted the default Life Cycle Assessment  value calculation for the raw material. According to him, ICAO's recognition is a strategic milestone for Indonesia to enter the global bioavtur market.\"This approval confirms that POME is recognized as a sustainable aviation fuel raw material with highly competitive emission values, capable of reducing emissions by up to 80 percent compared to fossil fuels,\" Lukman said, as quoted from a written statement on Thursday, December 11, 2025.","market":"sh","thumbnail":"https://statik.tempo.co/data/2025/08/21/id_1422554/1422554_720.jpg","type":0,"news_type":0,"thumbnails":["https://statik.tempo.co/data/2025/08/21/id_1422554/1422554_720.jpg"],"rights":{"source":"tempo_highlight","url":"https://en.tempo.co/read/2072723/icao-approves-palm-oil-waste-as-a-base-for-bioavtur","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://en.tempo.co/read/2072723/icao-approves-palm-oil-waste-as-a-base-for-bioavtur","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tempo_highlight","symbols":["LCA"],"gpt_icon":0},{"id":"2582373217","title":"Press Release: Opus Genetics Announces Financial Results for Third Quarter 2025 and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2582373217","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582373217?lang=en_us&edition=fundamental","pubTime":"2025-11-12 20:00","pubTimestamp":1762948800,"startTime":"0","endTime":"0","summary":"- Positive 3-month pediatric and 18-month adult clinical data from OPGx-LCA5 Phase 1/2 trial support the potential for restoring cone-mediated vision -. - Successful FDA RMAT meeting provides the potential for an accelerated regulatory pathway to approval for OPGx-LCA5 -. - OPGx-BEST1 gene therapy program underway with recruitment ongoing in Phase 1/2 trial for the treatment of BEST1 disease -. - Supplemental New Drug Application submission planned by year-end 2025 for Phentolamine Ophthalmic Solution 0.75% for the treatment of presbyopia -. - Strengthened capital position from recent equity offering and non-dilutive funding from patient advocacy groups -. \"We have taken critical steps in advancing our pipeline, including the positive data and successful outcome of our recent FDA meeting regarding our LCA5 program and the opening of recruitment in our BEST1 Phase 1/2 clinical trial,\" said George Magrath, M.D., Chief Executive Officer, Opus Genetics. \"We look forward to continuing this ","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","LCA","ARB","BK4139","IRD"],"gpt_icon":0},{"id":"1173108590","title":"China's First Carbon Label for Freeze-Dried Kale Powder Launched in Gansu","url":"https://stock-news.laohu8.com/highlight/detail?id=1173108590","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1173108590?lang=en_us&edition=fundamental","pubTime":"2025-11-08 03:10","pubTimestamp":1762542633,"startTime":"0","endTime":"0","summary":"A 560-acre export-grade freeze-dried kale powder production base in Zhangye City has received China's first carbon label certification for this product category, marking a new milestone in the...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LCA"],"gpt_icon":0},{"id":"2581776968","title":"Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2581776968","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581776968?lang=en_us&edition=fundamental","pubTime":"2025-11-05 05:01","pubTimestamp":1762290060,"startTime":"0","endTime":"0","summary":"RESEARCH TRIANGLE PARK, N.C., Nov.  04, 2025  (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage biopharmaceutical company developing gene therapies for the treatment of inherited","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/04/3180818/0/en/Opus-Genetics-Reports-Inducement-Grant-Under-Nasdaq-Listing-Rule-5635-c-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LCA","TQQQ","USJW.SI","NQmain","QID","SQQQ","PSQ","MNQmain","TSYW.SI","NVIW.SI","USAW.SI",".IXIC","QLD"],"gpt_icon":1},{"id":"2580421315","title":"Opus Genetics Featured on Good Morning America Spotlighting Breakthrough Gene Therapy Restoring Sight in Patients with Inherited Blindness","url":"https://stock-news.laohu8.com/highlight/detail?id=2580421315","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580421315?lang=en_us&edition=fundamental","pubTime":"2025-11-03 21:00","pubTimestamp":1762174800,"startTime":"0","endTime":"0","summary":"RESEARCH TRIANGLE PARK, N.C., Nov.  03, 2025  (GLOBE NEWSWIRE) -- Opus Genetics (Nasdaq: IRD), a clinical-stage biopharmaceutical company developing gene therapies for the treatment of inherited retin","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/03/3179205/0/en/Opus-Genetics-Featured-on-Good-Morning-America-Spotlighting-Breakthrough-Gene-Therapy-Restoring-Sight-in-Patients-with-Inherited-Blindness.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LCA"],"gpt_icon":0},{"id":"2579929415","title":"Bureau Veritas Showcases Three Key Net-Zero Transformation Solutions at Energy Taiwan","url":"https://stock-news.laohu8.com/highlight/detail?id=2579929415","media":"prnewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579929415?lang=en_us&edition=fundamental","pubTime":"2025-10-29 15:32","pubTimestamp":1761723120,"startTime":"0","endTime":"0","summary":"TAIPEI, Oct. 29, 2025 /PRNewswire/ --As one of the world's leading testing, inspection, and certification companies, Bureau Veritas  will participate in Energy Taiwan 2025, organized by SEMI and the Taiwan External Trade Development Council . This year's exhibition, themed \"Towards Net-Zero Taiwan,\" will take place from October 29 to 31 at Taipei Nangang Exhibition Center, Hall 1 .During the exhibition, BV will highlight its comprehensive solutions under the three key pillars of net-zero transformation — New Energy, Sustainability, and Cybersecurity — demonstrating BV's strong capabilities in supporting global green transition and sustainable development.As smart manufacturing and IoT applications continue to expand, BV provides comprehensive cybersecurity testing and certification services, including product security testing, penetration testing, and information security & AI management system . These services help enterprises str","market":"other","thumbnail":"https://mma.prnewswire.com/media/2808071/Bureau_Veritas.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/2808071/Bureau_Veritas.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/bureau-veritas-showcases-three-key-net-zero-transformation-solutions-at-energy-taiwan-302598082.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LCA","BK4124","BV","BK4120","CPS"],"gpt_icon":0},{"id":"2575529055","title":"Opus Genetics to Participate in Chardan's 9th Annual Genetic Medicines Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2575529055","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575529055?lang=en_us&edition=fundamental","pubTime":"2025-10-14 20:00","pubTimestamp":1760443200,"startTime":"0","endTime":"0","summary":"RESEARCH TRIANGLE PARK, N.C., Oct.  14, 2025  (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (the “Company” or “Opus Genetics”), a clinical-stage biopharmaceutical company developing gene thera","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/14/3166083/0/en/Opus-Genetics-to-Participate-in-Chardan-s-9th-Annual-Genetic-Medicines-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LCA","MDCO"],"gpt_icon":0},{"id":"2572514715","title":"Opus Genetics to Present at Upcoming Medical and Industry Conferences in October 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2572514715","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572514715?lang=en_us&edition=fundamental","pubTime":"2025-10-02 20:00","pubTimestamp":1759406400,"startTime":"0","endTime":"0","summary":"RESEARCH TRIANGLE PARK, N.C., Oct.  02, 2025  (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage biopharmaceutical company developing gene therapies for the treatment of inherited","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/02/3160325/0/en/Opus-Genetics-to-Present-at-Upcoming-Medical-and-Industry-Conferences-in-October-2025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LCA"],"gpt_icon":0},{"id":"2571034156","title":"Opus Genetics Reports Positive Pediatric Data from OPGx-LCA5 Phase 1/2 Trial in Leber Congenital Amaurosis Type 5 (LCA5)","url":"https://stock-news.laohu8.com/highlight/detail?id=2571034156","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571034156?lang=en_us&edition=fundamental","pubTime":"2025-09-30 19:00","pubTimestamp":1759230000,"startTime":"0","endTime":"0","summary":"Pediatric participants demonstrated large gains in cone-mediated vision; therapy remains well tolerated with no ocular serious adverse events or dose-limiting toxicitiesLasting, durable responses obse","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/09/30/3158427/0/en/Opus-Genetics-Reports-Positive-Pediatric-Data-from-OPGx-LCA5-Phase-1-2-Trial-in-Leber-Congenital-Amaurosis-Type-5-LCA5.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LCA"],"gpt_icon":0},{"id":"2571725848","title":"Envision Energy Earns \"Green Passport\" EPD, Raising the Benchmark for Sustainable Wind Turbines","url":"https://stock-news.laohu8.com/highlight/detail?id=2571725848","media":"prnewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571725848?lang=en_us&edition=fundamental","pubTime":"2025-09-29 10:41","pubTimestamp":1759113660,"startTime":"0","endTime":"0","summary":"MILAN, Sept. 29, 2025 /PRNewswire/ -- Envision Energy, a global leader in green technology, announced that its key wind turbine models, the EN-171/6.0/6.25/6.5 and EN-182/6.25, have been published the Environmental Product Declaration  on EPDItaly platform. This achievement highlights Envision Energy's sustainability leadership and provides internationally recognized green credentials for customers and partners, helping shift the industry from pure price competition to full life-cycle environmental value competition, paving the way for a greener future.Digital Carbon Management Tools: Envision Energy has created a digital energy and carbon management platform covering global sites, major products, and core supply chains. This time, we utilized the carbon accounting and life cycle assessment  pl","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/envision-energy-earns-green-passport-epd-raising-the-benchmark-for-sustainable-wind-turbines-302569116.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EPD.AU","BK4006","LU1150488218.USD","LCA","LU1150488135.SGD","BK4588","BK4561","BK4590","EPD","BK4585","BK4144","AP","BK4213","EP"],"gpt_icon":0},{"id":"2566979961","title":"Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2566979961","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566979961?lang=en_us&edition=fundamental","pubTime":"2025-09-12 20:00","pubTimestamp":1757678400,"startTime":"0","endTime":"0","summary":"RESEARCH TRIANGLE PARK, N.C., Sept.  12, 2025  (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage biopharmaceutical company developing gene therapies for the treatment of inherite","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/09/12/3149159/0/en/Opus-Genetics-Reports-Inducement-Grant-Under-Nasdaq-Listing-Rule-5635-c-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2095319765.USD","LU2210150020.SGD","NQmain","TSYW.SI","QLD","BK4585","TQQQ","IE00BGHQF748.EUR","PSQ","IE00B3QW5Z07.USD","LU2210149790.SGD","SQQQ","USAW.SI","BK4112","BK4588","IE00B64PRP62.GBP","NVIW.SI","LU0314104364.USD",".IXIC","NDAQ","LCA","QID","USJW.SI","IE00BKPKM429.USD","MNQmain"],"gpt_icon":1},{"id":"2564712323","title":"Opus Genetics Doses First Patient in Pivotal LYNX-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients With Visual Disturbances Under Mesopic, Low-Contrast Conditions","url":"https://stock-news.laohu8.com/highlight/detail?id=2564712323","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564712323?lang=en_us&edition=fundamental","pubTime":"2025-09-04 20:00","pubTimestamp":1756987200,"startTime":"0","endTime":"0","summary":"RESEARCH TRIANGLE PARK, N.C., Sept.  04, 2025  (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage biopharmaceutical company developing gene therapies for inherited retinal disease","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/09/04/3144432/0/en/Opus-Genetics-Doses-First-Patient-in-Pivotal-LYNX-3-Phase-3-Trial-Evaluating-Phentolamine-Ophthalmic-Solution-0-75-in-Keratorefractive-Patients-With-Visual-Disturbances-Under-Mesop.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PRK","LCA","BK4211"],"gpt_icon":0},{"id":"2564913804","title":"Press Release: Opus Genetics Appoints Rob Gagnon as Chief Financial Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2564913804","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564913804?lang=en_us&edition=fundamental","pubTime":"2025-09-02 20:00","pubTimestamp":1756814400,"startTime":"0","endTime":"0","summary":"RESEARCH TRIANGLE PARK, N.C., Sept. 02, 2025  -- Opus Genetics, Inc. , a clinical-stage biopharmaceutical company developing gene therapies for inherited retinal diseases  and small molecule therapies for other ophthalmic disorders, today announced the appointment of Rob Gagnon, CPA, MBA, as Chief Financial Officer.Mr. Gagnon is an accomplished biotech executive with more than two decades of financial and operational leadership experience in both public and private companies. He has raised over $2 billion in capital, executed multiple strategic transactions, and held senior roles guiding companies through IPOs, late-stage clinical development, commercial launches, and M&A.Opus Genetics is a clinical-stage biopharmaceutical company developing gene therapies for the treatment of inherited retinal diseases  and small molecule therapies for other ophthalmic disorders. The Company's pipeline features AAV-based gene therapies targeting inherited retinal diseases including Leber congenital am","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LCA","BK4007","IRD","BK4139"],"gpt_icon":0},{"id":"2562746647","title":"Opus Genetics Inherited Retinal Disease Programs Featured at Medical and Industry Conferences in September","url":"https://stock-news.laohu8.com/highlight/detail?id=2562746647","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562746647?lang=en_us&edition=fundamental","pubTime":"2025-08-27 20:00","pubTimestamp":1756296000,"startTime":"0","endTime":"0","summary":"RESEARCH TRIANGLE PARK, N.C., Aug.  27, 2025  (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq:IRD), a clinical-stage biopharmaceutical company developing gene therapies for the treatment of inherited ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/08/27/3139962/0/en/Opus-Genetics-Inherited-Retinal-Disease-Programs-Featured-at-Medical-and-Industry-Conferences-in-September.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LCA"],"gpt_icon":0},{"id":"2560074902","title":"Opus Genetics Announces FDA Clearance of IND Application for Gene Therapy Candidate OPGx-BEST1","url":"https://stock-news.laohu8.com/highlight/detail?id=2560074902","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2560074902?lang=en_us&edition=fundamental","pubTime":"2025-08-18 20:00","pubTimestamp":1755518400,"startTime":"0","endTime":"0","summary":"– Phase 1/2 trial expected to initiate in 2H 2025 in patients with BEST1 inherited retinal disease RESEARCH TRIANGLE PARK, N.C., Aug.  18, 2025  (GLOBE NEWSWIRE) -- Opus Genetics (Nasdaq: IRD), a clin","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/08/18/3134953/0/en/Opus-Genetics-Announces-FDA-Clearance-of-IND-Application-for-Gene-Therapy-Candidate-OPGx-BEST1.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LCA"],"gpt_icon":0},{"id":"2559981194","title":"Opus Genetics Announces Financial Results for Second Quarter 2025 and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2559981194","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559981194?lang=en_us&edition=fundamental","pubTime":"2025-08-14 04:30","pubTimestamp":1755117000,"startTime":"0","endTime":"0","summary":"- Positive 12-month Phase 1/2 clinical data in adult cohort and early pediatric clinical data support potential for meaningful vision restoration with OPGx-LCA5 -- FDA grants Regenerative Medicine Adv","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/08/13/3133018/0/en/Opus-Genetics-Announces-Financial-Results-for-Second-Quarter-2025-and-Provides-Corporate-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LCA","LU1721427968.SGD","LU2413665964.HKD","LU1596574779.USD","BK4585","BK4086","LU1165135440.EUR","AOS","BK4588","LU1620156130.USD","LU2413666004.HKD","LU1543694498.USD","LU1620156213.USD","LU2380233275.USD"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":17,"code":"91000000","status":"200"}]}}